Advanced Search:
Equity Index Forex Crypto Commodity

NBIX - Neurocrine Biosciences

$138.89  2.9 (2.13%)

Updated: 17:08 Apr 29, 2024 EST

Next Hour's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Session's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Week's AI Forecast

N/A

Trend's Accuracy (AI)

N/A

Neurocrine Biosciences's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

NEUROCRINE BIOSCIENCES - HISTORICAL DATA 6M

  • Last price

    $ 138.89

  • Daily change

    $ 2.9

  • Previous Close

    $ 135.99

  • Last Updated

    17:08 Apr 29, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 -0.16 0.05 0.17 0.14

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 1.27 1.25 1.24 1.18

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
N/A N/A 50.9% 41.9%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
0 -100% 137.29 -0.06% 137.37 6.6% 128.86

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
2.77 34.21 0.73 73.47

Neurocrine Biosciences Technical Analysis News

Neurocrine Biosciences

12780 El Camino Real
San Diego, CA 92130
United States
858 617 7600
http://www.neurocrine.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 884
Description

Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Corporate Governance

Neurocrine Biosciences, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 4. The pillar scores are Audit: 6; Board: 6; Shareholder Rights: 4; Compensation: 4.

NEUROCRINE BIOSCIENCES'S HOLDERS RANK

List of holders with stock participation in Neurocrine Biosciences.

Holder Rank Holder Shares Date Reported % Out Value